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Background: Low vitamin D and/or sun exposure have been associated with increased 
risk of multiple sclerosis (MS) onset. However, comparatively, few studies have prospec-
tively examined associations between these factors and clinical course.
Objectives: To evaluate the association of sun exposure parameters and vitamin D 
levels with conversion to MS and relapse risk in a prospectively monitored cohort of 
145 participants followed after a first demyelinating event up to 5-year review (AusLong 
Study).
Methods: Sun exposure prior to and after onset measured by annual questionnaire; 
ultraviolet radiation (UVR) “load” estimated by location of residence over the life course 
and ambient UVR levels. Serum 25-hydroxyvitamin D [25(OH)D] concentrations mea-
sured at baseline, 2/3-year, and 5-year review. MS conversion and relapse assessed by 
neurologist assessment and medical record review.
results: Over two-thirds (69%) of those followed to 5-year review (100/145) converted 
to MS, with a total of 252 relapses. Higher pre-MS onset sun exposure was associated 
with reduced risk of MS conversion, with internal consistency between measures and 
dose–response relationships. Analogous associations were also seen with risk of relapse, 
albeit less strong. No consistent associations were observed between postonset sun 
exposure and clinical course, however. Notably, those who increased their sun exposure 
during follow-up had significantly reduced hazards of MS conversion and relapse. Serum 
25(OH)D levels and vitamin D supplementation were not associated with conversion to 
MS or relapse hazard.
conclusion: We found that preonset sun exposure was protective against subsequent 
conversion to MS and relapses. While consistent associations between postonset sun 
exposure or serum 25(OH)D level and clinical course were not evident, possibly masked 
by behavior change, those participants who markedly increased their sun exposure 
demonstrated a reduced MS conversion and relapse hazard, suggesting beneficial 
effects of sun exposure on clinical course.
Keywords: multiple sclerosis, vitamin D, sun exposure, ultraviolet radiation, relapse, behaviour change, first 
demyelinating event, cis
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inTrODUcTiOn
Of the various environmental and behavioral—and thus poten­
tially modifiable—risk factors implicated in the onset and pro­
gression of multiple sclerosis (MS), evidence for a role for vitamin 
D and ultraviolet radiation (UVR) exposure has been among the 
most consistent, on a par with smoking and Epstein­Barr virus 
exposure. As we have discussed elsewhere (1), vitamin D and 
UVR exposure provide an excellent example of epidemiologi­
cal consistency with both onset (2–15) and clinical course (12, 
16–25), being supported by measures of preonset time in the 
sun, vitamin D intake, and direct measurement using measures 
of current sun exposure and vitamin D metabolites, and even 
indirectly by the well­recognized latitudinal gradient in MS 
prevalence and incidence (26, 27). Additional evidence comes 
from genetic studies that have detected significant associations 
with polymorphisms within or near vitamin D­associated genes 
(28), as well as by recent Mendelian randomization studies that 
implicated genetic differences in 25(OH)D levels in the develop­
ment of MS (29, 30).
All this taken together has led us to wait with anticipation for 
the results of UV treatment and vitamin D supplementation as 
interventions against MS outcomes in randomized trials (31). 
However, the results published thus far have had inconsistent 
findings. Some smaller studies showed some benefit of vitamin 
D supplementation, either alone or in addition to established 
immunomodulatory therapy (32, 33), but others have shown 
no effects with some or all outcomes (32, 34–38). Results from 
larger trials are yet forthcoming, including the PrevANZ study of 
vitamin D supplementation as an intervention against progres­
sion to clinically definite MS following a first demyelinating event 
(FDE), as well as the larger SOLAR study investigating vitamin 
D supplementation as an add­on to interferon­beta therapy (31). 
Additionally, the PhoCIS Study trial of UVR phototherapy as an 
intervention in patients with clinically isolated syndrome (39) 
recently reported its preliminary results, indicating a 30% reduc­
tion in subsequent conversion to MS in the treated vs. untreated 
group (40).
The disparity between the relative consistency of the obser­
vational studies of the past two decades, mainly focused on 
MS onset, and these first randomized trials, mainly focused on 
clinical course, has been perplexing. One suggestion has been 
that sun exposure has benefits beyond vitamin D (10, 41); and 
therefore significant findings based on UVR­derived vitamin 
D from observational studies do not translate into effect in 
the vitamin D supplementation intervention studies as only 
the effect of vitamin D is being tested. Others have suggested 
that the null hypothesis—that vitamin D/UV associations in 
observational studies merely represent unmeasured confound­
ing—is indicated by the results from randomized controlled 
trials (42, 43).
To better understand the roles of sun/UVR exposure and vita­
min D in MS disease activity and progression, we analyzed sun 
exposure before and after onset of MS, as well as serum 25(OH)
D levels and vitamin D supplementation after onset, for their 
associations with clinical outcomes in a prospective cohort study 
of participants followed since FDE.
MaTerials anD MeThODs
Participants and setting
The Ausimmune Study is a population­based multicentre case­
control study designed to capture all incident FDE cases in four 
regions of eastern Australia: Brisbane city (latitude 27° South), 
Newcastle city and surrounds (33° South), Geelong city and the 
Western Districts of Victoria (37° South), and the state of Tasmania 
(43° South) (8). The Ausimmune Longitudinal (AusLong) Study, 
which built upon the original Ausimmune Study, seeks to elu­
cidate environmental, genetic and personal risk factors for the 
onset and early progression of MS in case participants in the 
Ausimmune Study who had a first clinical diagnosis of CNS 
demyelination (FCD) and were thus at high risk of developing 
MS (44). Since 2009 the AusLong Study has followed Ausimmune 
Study cases (retention rate 84.6%). The ethics committee of all 
participating centers approved the study; all participants signed 
written informed consent.
The cohort for the present analysis is slightly different to the 
original Ausimmune case cohort (8, 45). Following review of 
clinical information at the 5­year review, three of the original 
282 cases were identified as not having had an MS­associated 
FDE (one neuromyelitis optica spectrum disorder, one Susac’s 
syndrome, and one pineal germinoma). Additionally, three 
cases originally recorded as relapse­onset were reclassified to 
progressive­onset on the basis of a clinical course devoid of 
discrete events but instead steady deterioration in function more 
befitting a progressive disease course (46). With these adjust­
ments, there were 260 relapse­onset cases (170 of whom had their 
FDE just prior to initial presentation and inclusion in the study 
and whom we define here as “classic FDE cases,” and 90 whose 
FDE had occurred at an earlier date). These participants were thus 
diagnosed as having MS on presentation to the study. In addition, 
there were 19 case participants with progressive­onset disease.
Our principal analysis was restricted to “classic FDE cases,” i.e., 
those participants with a relapse­onset presentation whose first 
known event occurred just prior to notification to, and participa­
tion, in the Ausimmune Study (n = 170). Accordingly, all of the 
clinical events that occurred for these individuals did so during 
the prospective follow­up period, giving us greatest confidence 
in the reliability of these data. The participants with relapse­onset 
presentation who had had an FDE more distant from their first 
participation in the Ausimmune Study, as well as the progressive­
onset cases, were not included in this analysis.
exposure Measures
Preonset sun exposure behaviors were queried at baseline, 
including time spent in the sun in various age categories were 
queried by questionnaire and life calendar: sun exposure during 
6–10, 11–15, and 16–20 years periods, and 1, 2, and 3 years prior 
to baseline review were specifically queried by questionnaire. In 
addition, summer and winter sun exposure from age 6 onward 
were queried by personal work and residence calendar, including 
time spent outside and the location of residence. From the life 
calendar, we used satellite data to estimate the average daily dose 
of UVR for each month over each year of life according to the 
latitude and longitude of the location of residence. We combined 
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this with data on time outdoors in each year of life to calculate 
the total summer and winter UVR exposures for each individual 
for various periods of life, hereafter referred to as UVR­load. 
Postonset sun exposure for each year of follow­up in summer and 
winter was queried at each review (queried as <1, 1–2, 2–3, 3–4, 
and 4+ h/day and coded as 0, 1, 2, 3, and 4).
Change in sun exposure between baseline and 5­year review 
was calculated for summer and winter, and for weekdays, week­
ends, and holidays. Decreases of −4, −3, or −2 correspond to 
moving 4, 3, or 2 increments down in the sun exposure parameter 
between reviews, and reciprocally, +2, +3, or +4 correspond to 
moving 2, 3, or 4 increments up in the sun exposure parameter 
between reviews. Values of 0, as well as +1 and −1, were inter­
preted as the participant’s sun exposure for that parameter being 
unchanged between reviews, for example 1–2 h/day at both time 
points.
Serum was taken at each of the three face­to­face reviews 
(baseline, 2/3­year, 5­year), from which serum 25­hydroxy­
vitamin D3 (25(OH)D) levels were measured. Baseline serum 
25(OH)D levels were measured at RDDT in Victoria, Australia, 
whereas 2/3 and 5­year serum 25(OH)D levels were measured 
at Canterbury Labs in New Zealand. The 25(OH)D levels from 
these separate assays were compared in a subset of 50 samples 
that were measured with both assays and also at a laboratory 
at the US Centers for Disease Control and Prevention (CDC) that 
uses a 25(OH)D assay that is standardized to the NIST­Ghent 
reference measurement procedure. Based on these data we 
calculated a conversion algorithm to standardize the 25(OH)D 
values from each of the assays to the CDC assay using Deming 
regression. The (study baseline) RMIT translation function was
 Standard25(OH)D As­measured OH D= ×(( ( ) ) ) −25 0 87 1 74. . . 
And for the samples assayed at Canterbury Laboratories:
 Standard (OH)D= As­measured 25 OH D25 0 79 5 91(( ( ) ) ) +× . . . 
More comprehensive discussion of the methods involved in 
25(OH)D measurement and consolidation of metrics to a stand­
ard are described elsewhere (47).
Having standardized the 25(OH)D levels to the reference 
laboratory for all samples at the three measurement time points, 
deseasonalized 25(OH)D levels were estimated using separate 
sinusoidal regression functions for each of the four study sites 
[given the widely disparate levels of ambient UVR and thus 
seasonal patterns of variation in 25(OH)D], using functions 
described previously (17). We estimated serum 25(OH)D levels 
at November 19 and May 20, the start of the summer and winter 
6­month seasons.
clinical course Measures
Two clinical outcomes were evaluated, namely hazard of conver­
sion to MS and hazard of relapse. Conversion to MS was defined 
primarily as the occurrence of two or more clinical demyelinating 
episodes, thus satisfying the diagnostic requirements of dis­
semination in space and time, or a single episode plus paraclini­
cal evidence, as per the 2005 McDonald criteria (48) including 
application of MRI criteria. Conversion to MS was reported at 
annual review and cross­checked with neurological records and 
confirmed by a study neurologist at 2/3 and 5 years. A relapse 
was defined according to the 2001 McDonald Criteria (49) as the 
acute or subacute appearance or reappearance of a neurological 
abnormality (lasting at least 24 h) in the absence of other potential 
explanatory factors. Relapses were reported at annual review and 
only relapses which were diagnosed and verified by a neurologist 
were included in the analysis.
Data analysis
Interreview differences in the proportions with different levels 
of the various sun/vitamin D­related covariates were assessed 
by Chi­square test, and thence by log­multinomial regression 
to determine the magnitude and significance of changes in each 
level of the covariates between reviews.
Predictors of hazard of MS conversion and of relapse were 
evaluated by Cox proportional hazards regression models, the 
latter for repeated events. Time at risk for both outcomes was 
defined as starting from the date of symptom onset. All covariates 
satisfied the proportional hazards assumption except that of study 
site for relapse analyses.
Time­varying covariates were extrapolated forwards in 
time from their measure as appropriate. Thus, while baseline­
measured covariates and preonset parameters such as preonset 
sun exposure behaviors were extrapolated forward to cover all 
events, time­varying behavioral covariates (e.g., longitudinal sun 
exposure and sun behavior) were extrapolated forward only to 
the next annual measure of that variable, whereas serum 25(OH)
D level was extrapolated forward only to 6 months from when 
the sample was taken, reflecting the greater variability of this 
parameter.
Tests for trend of categorical variables were undertaken by 
replacing the binary predictors with a single predictor, taking 
category rank scores.
All statistical analyses were conducted in Stata/SE 14.1 
(StataCorp LP, College Station, TX, USA).
resUlTs
The cohort comprised 170 persons; however, for the purposes 
of evaluating change in behavior, analysis was restricted to the 
145/170 persons who completed the 5­year review. There were no 
material differences between the total cohort and those complet­
ing the 5­year review (see Table  1), except for the proportion 
converting to MS and the number of recorded relapses, which 
were higher among those with follow­up to 5  years. During 
follow­up, 110 of 170 participants converted to clinically definite 
MS (64.7%) and experienced 265 relapses. Of the 145 participants 
who completed the 5­year review, 100 (69.0%) had converted to 
MS and between them had 252 relapses; 35 participants (24.1%) 
had no relapses during follow­up.
Of the participants completing 5­year review, over three­
quarters of the participants were female and the average age at 
study entry was 37.7 years. The largest proportions of participants 
were recruited in Tasmania (37.2%) and Queensland (26.2%). 
The average deseasonalized serum 25(OH)D concentration at 
baseline was 65.3 nmol/L, increasing to 70.3 nmol/L at five­year 
review.
TaBle 1 | Cohort characteristics, all persons and those who completed up to 5-year review.
all persons completed 5-year review Test for difference
n (%) n (%)
sex
Male
Female
38 (22.4)
132 (77.7)
31 (21.4)
114 (78.6)
p = 0.46
study site
QLD
NSW
VIC
TAS
49 (28.8)
26 (15.3)
33 (19.4)
62 (36.5)
38 (26.2)
24 (16.6)
29 (20.0)
54 (37.2)
p = 0.30
BMi at baselinea
Normal
Overweight
Obese
78 (46.4)
46 (27.4)
44 (26.2)
65 (44.8)
41 (28.3)
39 (26.9)
p = 0.58
Diagnosed with Ms during follow-up?
No
Yes
60 (35.3)
110 (64.7)
45 (31.0)
100 (69.0)
p = 0.005
number of relapses during study periodb
0
1
2
3
4–23
60 (35.3)
59 (34.7)
20 (11.8)
11 (6.5)
20 (11.8)
45 (31.0)
51 (35.2)
19 (13.1)
10 (6.9)
20 (13.8)
p = 0.015
Taking immunomodulatory medication at 5-year review?
No
Yes
72 (49.7%)
73 (50.3%)
Mean (sD; range)
Age (years) 37.6 (9.7; 18–58) 37.7 (9.6; 18–58) p = 0.73
As-measured serum 25(OH)D at baseline review (nmol/L)b 64.8 (28.9; 12.8–178.1) 63.9 (27.6; 12.8–142.5) p = 0.39
Deseasonalized serum 25(OH)D at baseline review (nmol/L)b 64.7 (28.1; 7.9–173.7) 65.3 (28.3; 7.9–173.7) p = 0.46
As-measured serum 25(OH)D at 5-year review (nmol/L)c 69.9 (26.5; 24.9–167.1)
Deseasonalized serum 25(OH)D at 5-year review (nmol/L)c 70.3 (26.2; 21.8–169.0)
EDSS at 5-year  
review,d median (IQR)
1.5 (1.0–2.0)
Test for difference in dichotomous or categorical variables between groups assessed by Chi-square test. Test for difference in normal continuous variables [serum 25(OH)D] 
assessed by Student’s t-test.
aExcludes two persons who did not have BMI measured at baseline.
bExcludes six persons who did not have serum 25(OH)D measured at baseline.
cExcludes four persons who did not have serum 25(OH)D measured at 5-year review.
dExcludes three persons who did not have EDSS measured at 5-year review.
QLD, Queensland study site; NSW, New South Wales study site; VIC, Victoria study site; TAS, Tasmania study site; BMI, body mass index; MS, multiple sclerosis; 25(OH)D, 
25-hydroxyvitamin D; EDSS, Expanded Disability Status Scale; IQR, interquartile range.
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association between recent and  
Preonset sun exposure and  
conversion to Ms and relapse
Higher preonset UVR­load parameters, both in summer and in 
winter, were associated with significantly reduced hazard of MS 
conversion (Table 2), most associations persisting on adjustment 
for age, sex and study site. More recent higher UVR exposure 
(UVR­load in the year of the FDE, 2 years before FDE, 3 years 
before study entry) were also significantly associated with a 
reduced risk of converting to MS, persisting on adjustment.
For relapse (Table 3), summer UVR­load at younger ages and 
most winter UVR­load parameters were significantly associated 
with a reduced relapse hazard, though none of these were robust 
to adjustment for age, sex, study site, and use of immunomodula­
tory medication.
Analogous results were seen for absolute durations of sun 
exposure (data not shown).
association between Post-FDe sun 
exposure and conversion to Ms and 
relapse
In contrast to the associations of preonset and peri­FDE sun 
exposure parameters with MS and relapse, post­FDE sun expo­
sure (duration and derived UVR­load) showed no consistent 
TaBle 2 | Preonset sun exposure measures and associations with hazard of MS conversion.
summer UVr measures and hazard of Ms conversion Winter UVr measures and hazard of Ms conversion
Failures/ 
person-years (rate)
hr (95% ci) Failures/ 
person-years (rate)
hr (95% ci)
Univariable adjusteda Univariable adjusteda
Summer UVR-load 6–10 years old (kJ/m2) Winter UVR-load 6–10 years old (kJ/m2)
0–228
>228–323
>323–383
>383–488
Trend:
35/83.36 (0.42)
31/138.17 (0.22)
26/123.21 (0.21)
18/103.78 (0.17)
1.00 (reference)
0.60 (0.36, 0.98)
0.56 (0.34, 0.91)
0.44 (0.25, 0.78)
p = 0.004
1.00 (reference)
0.73 (0.43, 1.25)
0.75 (0.42, 1.34)
0.47 (0.25, 0.86)
p = 0.020
0–31
>31–52
>52–100
>100–544
Trend:
33/88.78 (0.37)
33/124.15 (0.27)
22/125.50 (0.18)
22/110.09 (0.20)
1.00 (reference)
0.75 (0.46, 1.22)
0.53 (0.30, 0.92)
0.57 (0.33, 0.96)
p = 0.017
1.00 (reference)
0.87 (0.50, 1.52)
0.60 (0.32, 1.15)
0.46 (0.23, 0.92)
p = 0.025
Summer UVR-load 11–15 years old (kJ/m2) Winter UVR-load 11–15 years old (kJ/m2)
0–229
>229–313
>313–360
>360–482
Trend:
35/83.15 (0.42)
30/102.36 (0.29)
29/157.05 (0.19)
16/105.96 (0.15)
1.00 (reference)
0.71 (0.43, 1.18)
0.48 (0.29, 0.79)
0.39 (0.21, 0.72)
p = 0.001
1.00 (reference)
0.86 (0.51, 1.44)
0.62 (0.35, 1.09)
0.48 (0.25, 0.90)
p = 0.012
0–33
>33–53
>53–104
>104–530
Trend:
32/105.92 (0.30)
33/100.31 (0.33)
20/134.19 (0.15)
25/108.10 (0.23)
1.00 (reference)
1.07 (0.66, 1.74)
0.55 (0.31, 0.99)
0.78 (0.47, 1.29)
p = 0.093
1.00 (reference)
1.20 (0.69, 2.09)
0.63 (0.33, 1.19)
0.72 (0.39, 1.32)
p = 0.14
Summer UVR-load 16–20 years old (kJ/m2) Winter UVR-load 16–20 years old (kJ/m2)
0–188
>188–266
>266–337
>337–491
Trend:
36/86.43 (0.42)
29/103.58 (0.28)
28/131.22 (0.21)
17/127.29 (0.13)
1.00 (reference)
0.67 (0.41, 1.09)
0.55 (0.33, 0.92)
0.37 (0.21, 0.66)
p < 0.001
1.00 (reference)
0.72 (0.42, 1.23)
0.75 (0.44, 1.29)
0.52 (0.28, 0.97)
p = 0.054
0–28
>28–45
>45–80
>80–556
Trend:
36/88.02 (0.41)
34/119.76 (0.28)
19/111.86 (0.17)
21/128.88 (0.16)
1.00 (reference)
0.73 (0.46, 1.15)
0.47 (0.26, 0.84)
0.46 (0.27, 0.76)
p = 0.001
1.00 (reference)
0.81 (0.48, 1.36)
0.52 (0.27, 1.00)
0.48 (0.27, 0.84)
p = 0.008
Summer UVR-load 21–25 years old (kJ/m2) Winter UVR-load 21–26 years old (kJ/m2)
0–148
>148–237
>237–329
>329–494
Trend:
28/74.94 (0.37)
29/88.83 (0.33)
22/113.64 (0.19)
20/154.98 (0.13)
1.00 (reference)
0.81 (0.46, 1.43)
0.54 (0.30, 0.99)
0.38 (0.21, 0.69)
p = 0.001
1.00 (reference)
0.96 (0.53, 1.74)
0.68 (0.35, 1.31)
0.50 (0.26, 0.96)
p = 0.020
0–24
>24–44
>44–85
>85–285
Trend:
34/83.92 (0.41)
24/109.24 (0.22)
17/104.21 (0.16)
24/135.03 (0.18)
1.00 (reference)
0.60 (0.35, 1.04)
0.45 (0.25, 0.83)
0.50 (0.30, 0.83)
p = 0.006
1.00 (reference)
0.56 (0.31, 1.01)
0.46 (0.24, 0.88)
0.47 (0.27, 0.82)
p = 0.010
Summer UVR-load 26–30 years old (kJ/m2) Winter UVR-load 26–30 years old (kJ/m2)
0–143
>143–228
>228–329
>329–510
Trend:
27/65.73 (0.41)
26/86.43 (0.30)
20/102.05 (0.20)
17/148.47 (0.12)
1.00 (reference)
0.73 (0.42, 1.29)
0.53 (0.30, 0.95)
0.32 (0.17, 0.61)
p < 0.001
1.00 (reference)
0.82 (0.44, 1.55)
0.58 (0.30, 1.10)
0.40 (0.19, 0.85)
p = 0.012
0–21
>21–44
>44–70
>70–411
Trend:
29/80.78 (0.36)
26/104.91 (0.25)
19/93.85 (0.20)
16/123.12 (0.13)
1.00 (reference)
0.76 (0.44, 1.29)
0.62 (0.34, 1.14)
0.42 (0.23, 0.78)
p = 0.005
1.00 (reference)
0.80 (0.43, 1.49)
0.69 (0.34, 1.41)
0.37 (0.19, 0.75)
p = 0.005
Summer UVR-load 31–35 years old (kJ/m2) Winter UVR-load 31–35 years old (kJ/m2)
0–136
>136–218
>218–328
>328–465
Trend:
26/65.70 (0.40)
17/76.95 (0.22)
18/109.99 (0.16)
16/96.35 (0.17)
1.00 (reference)
0.59 (0.31, 1.12)
0.47 (0.25, 0.87)
0.46 (0.25, 0.85)
p = 0.009
1.00 (reference)
0.84 (0.41, 1.74)
0.79 (0.36, 1.72)
0.78 (0.37, 1.62)
p = 0.50
0–22
>22–37
>37–69
>69–214
Trend:
24/78.62 (0.31)
19/105.33 (0.18)
19/81.31 (0.23)
15/83.74 (0.18)
1.00 (reference)
0.66 (0.35, 1.23)
0.82 (0.45, 1.49)
0.67 (0.37, 1.22)
p = 0.30
1.00 (reference)
0.77 (0.39, 1.53)
0.92 (0.46, 1.82)
0.52 (0.26, 1.05)
p = 0.12
Summer UVR-load in 3 years before study entryb (kJ/m2) Winter UVR-load in 3 years before study entry (kJ/m2)
0–80
>80–90
>90–152
>152–290
Trend:
28/103.52 (0.27)
32/62.88 (0.51)
29/92.00 (0.32)
20/178.92 (0.11)
1.00 (reference)
1.60 (0.92, 2.76)
1.09 (0.65, 1.80)
0.44 (0.25, 0.78)
p = 0.001
1.00 (reference)
1.74 (0.92, 3.29)
1.23 (0.71, 2.13)
0.56 (0.29, 1.05)
p = 0.019
0–17
>17–27
>27–41
>41–125
Trend:
32/120.02 (0.27)
33/64.41 (0.51)
22/112.22 (0.20)
22/140.66 (0.16)
1.00 (reference)
1.63 (0.99, 2.67)
0.80 (0.46, 1.40)
0.63 (0.37, 1.05)
p = 0.019
1.00 (reference)
1.51 (0.83, 2.75)
0.52 (0.22, 1.19)
0.28 (0.11, 0.71)
p = 0.002
UVR-load in summer in year of FDE (kJ/m2) UVR-load in winter in year of FDE (kJ/m2)
7–28
>28–47
>47–69
>69–96
Trend:
33/46.32 (0.71)
28/92.25 (0.30)
26/151.17 (0.17)
19/133.64 (0.14)
1.00 (reference)
0.52 (0.29, 0.91)
0.32 (0.19, 0.55)
0.26 (0.15, 0.47)
p < 0.001
1.00 (reference)
0.56 (0.31, 1.01)
0.52 (0.24, 0.75)
0.34 (0.18, 0.64)
p < 0.001
1–5
>5–9
>9–14
>14–53
Trend:
38/71.14 (0.53)
23/128.92 (0.18)
23/112.29 (0.21)
22/111.03 (0.20)
1.00 (reference)
0.43 (0.26, 0.73)
0.47 (0.27, 0.81)
0.46 (0.28, 0.74)
p = 0.004
1.00 (reference)
0.47 (0.28, 0.82)
0.46 (0.25, 0.84)
0.36 (0.19, 0.66)
p = 0.001
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TaBle 3 | Preonset sun exposure measures and associations with relapse hazard.
summer UVr measures and relapse hazard Winter UVr measures and relapse hazard
Failures/person-
years (rate)
hr (95% ci) Failures/person-
years (rate)
hr (95% ci)
Univariable adjusteda Univariable adjusteda
Summer UVR-load 6–10 years old (kJ/m2) Winter UVR-load 6–10 years old (kJ/m2)
0–228
>228–323
>323–383
>383–488
Trend:
66/235.56 (0.28)
77/262.48 (0.29)
40/220.65 (0.18)
24/173.87 (0.14)
1.00 (reference)
1.16 (0.66, 2.06)
0.87 (0.51, 1.50)
0.48 (0.28, 0.83)
p = 0.006
1.00 (reference)
1.11 (0.70, 1.77)
0.92 (0.59, 1.42)
0.54 (0.34, 0.87)
p = 0.010
0–31
>31–52
>52–100
>100–544
Trend:
59/231.23 (0.26)
51/258.75 (0.20)
47/215.54 (0.22)
50/187.05 (0.27)
1.00 (reference)
0.75 (0.46, 1.24)
0.82 (0.43, 1.55)
0.76 (0.40, 1.45)
p = 0.44
1.00 (reference)
0.81 (0.51, 1.27)
0.97 (0.59, 1.58)
0.83 (0.45, 1.53)
p = 0.68
Summer UVR-load 11–15 years old (kJ/m2) Winter UVR-load 11–15 years old (kJ/m2)
0–229
>229–313
>313–360
>360–482
Trend:
66/234.11 (0.28)
76/229.39 (0.33)
39/259.77 (0.15)
26/169.30 (0.15)
1.00 (reference)
1.22 (0.70, 2.14)
0.70 (0.43, 1.14)
0.55 (0.29, 1.08)
p = 0.015
1.00 (reference)
1.26 (0.78, 2.02)
0.85 (0.56, 1.30)
0.67 (0.38, 1.19)
p = 0.072
0–33
>33–53
>53–104
>104–530
Trend:
61/237.34 (0.26)
48/235.30 (0.20)
43/218.56 (0.20)
55/201.37 (0.27)
1.00 (reference)
0.73 (0.45, 1.18)
0.73 (0.39, 1.36)
0.76 (0.42, 1.38)
p = 0.39
1.00 (reference)
0.70 (0.45, 1.09)
0.81 (0.50, 1.30)
0.87 (0.50, 1.49)
p = 0.76
Summer UVR-load 16–20 years old (kJ/m2) Winter UVR-load 16–20 years old (kJ/m2)
0–188
>188–266
>266–337
>337–491
Trend:
75/232.69 (0.32)
63/222.79 (0.28)
43/244.31 (0.18)
26/192.78 (0.14)
1.00 (reference)
0.94 (0.52, 1.72)
0.70 (0.42, 1.16)
0.51 (0.24, 1.07)
p = 0.028
1.00 (reference)
0.95 (0.54, 1.66)
0.85 (0.53, 1.35)
0.79 (0.41, 1.51)
p = 0.38
0–28
>28–45
>45–80
>80–556
Trend:
78/239.42 (0.33)
52/254.66 (0.20)
45/192.52 (0.23)
32/205.97 (0.16)
1.00 (reference)
0.70 (0.42, 1.15)
0.73 (0.36, 1.45)
0.42 (0.24, 0.71)
p = 0.002
1.00 (reference)
0.73 (0.48, 1.12)
0.82 (0.43, 1.54)
0.62 (0.39, 0.98)
p = 0.078
Summer UVR-load 21–25 years old (kJ/m2) Winter UVR-load 21–26 years old (kJ/m2)
0–148
>148–237
>237–329
>329–494
Trend:
60/194.49 (0.31)
36/196.10 (0.18)
63/210.98 (0.30)
33/227.37 (0.15)
1.00 (reference)
0.66 (0.37, 1.16)
1.07 (0.59, 1.95)
0.56 (0.29, 1.09)
p = 0.29
1.00 (reference)
0.78 (0.51, 1.18)
1.37 (0.83, 2.26)
1.06 (0.61, 1.86)
p = 0.36
0–24
>24–44
>44–85
>85–285
Trend:
66/230.68 (0.29)
51/207.96 (0.25)
19/197.42 (0.10)
56/192.87 (0.29)
1.00 (reference)
0.96 (0.55, 1.66)
0.34 (0.17, 0.65)
0.79 (0.45, 1.37)
p = 0.19
1.00 (reference)
1.16 (0.73, 1.83)
0.50 (0.27, 0.92)
1.11 (0.68, 1.81)
p = 0.98
Summer UVR-load 26–30 years old (kJ/m2) Winter UVR-load 26–30 years old (kJ/m2)
0–143
>143–228
>228–329
>329–510
Trend:
50/168.47 (0.30)
43/214.71 (0.20)
43/160.88 (0.27)
25/218.57 (0.11)
1.00 (reference)
0.68 (0.40, 1.17)
0.89 (0.41, 1.91)
0.45 (0.24, 0.86)
p = 0.093
1.00 (reference)
0.89 (0.51, 1.54)
1.25 (0.61, 2.56)
1.00 (0.47, 2.11)
p = 0.69
0–21
>21–44
>44–70
>70–411
Trend:
46/218.58 (0.21)
51/198.80 (0.26)
25/204.45 (0.12)
39/140.81 (0.28)
1.00 (reference)
1.22 (0.73, 2.04)
0.46 (0.26, 0.82)
0.90 (0.44, 1.82)
p = 0.35
1.00 (reference)
1.45 (0.89, 2.37)
0.75 (0.42, 1.32)
1.22 (0.65, 2.29)
p = 0.87
Summer UVR-load 31–35 years old (kJ/m2) Winter UVR-load 31–35 years old (kJ/m2)
0–136
>136–218
>218–328
>328–465
Trend:
37/156.09 (0.24)
22/165.80 (0.13)
43/187.47 (0.23)
21/149.85 (0.14)
1.00 (reference)
0.53 (0.27, 1.05)
0.99 (0.46, 2.10)
0.68 (0.35, 1.31)
p = 0.72
1.00 (reference)
0.71 (0.39, 1.27)
1.36 (0.69, 2.67)
1.49 (0.69, 3.21)
p = 0.20
0–22
>22–37
>37–69
>69–214
Trend:
34/200.37 (0.17)
25/167.84 (0.15)
32/163.86 (0.20)
32/127.14 (0.25)
1.00 (reference)
0.98 (0.52, 1.84)
0.92 (0.49, 1.72)
0.97 (0.42, 2.23)
p = 0.89
1.00 (reference)
1.20 (0.66, 2.17)
1.18 (0.61, 2.27)
1.75 (0.75, 4.10)
p = 0.26
summer UVr measures and hazard of Ms conversion Winter UVr measures and hazard of Ms conversion
Failures/ 
person-years (rate)
hr (95% ci) Failures/ 
person-years (rate)
hr (95% ci)
Univariable adjusteda Univariable adjusteda
UVR-load in summer 2 years before FDE (kJ/m2) UVR-load in winter 2 years before FDE (kJ/m2)
7–28
>28–50
>50–69
>69–96
Trend:
32/46.07 (0.70)
29/106.24 (0.27)
27/143.46 (0.19)
20/135.22 (0.15)
1.00 (reference)
0.49 (0.28, 0.84)
0.36 (0.21, 0.61)
0.29 (0.16, 0.52)
p < 0.001
1.00 (reference)
0.49 (0.28, 0.85)
0.49 (0.28, 0.83)
0.36 (0.19, 0.68)
p = 0.003
1–5
>5–9
>9–14
>14–53
Trend:
40/76.92 (0.52)
23/123.15 (0.19)
25/120.84 (0.21)
20/110.08 (0.18)
1.00 (reference)
0.45 (0.27, 0.76)
0.48 (0.29, 0.79)
0.44 (0.26, 0.74)
p = 0.002
1.00 (reference)
0.43 (0.25, 0.75)
0.52 (0.29, 0.96)
0.33 (0.17, 0.62)
p = 0.001
Results in bold denote statistical significance (p < 0.05). Results in italics are for tests of trend.
aAdjusted models for MS include adjustment for age, sex, and study site.
bTwo persons did not have data on their summer UVR-load in the 3 years preceding study entry.
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summer UVr measures and relapse hazard Winter UVr measures and relapse hazard
Failures/person-
years (rate)
hr (95% ci) Failures/person-
years (rate)
hr (95% ci)
Univariable adjusteda Univariable adjusteda
Summer UVR-load in 3 years before study entryb (kJ/m2) Winter UVR-load in 3 years before study entry (kJ/m2)
0–80
>80–90
>90–152
>152–290
Trend:
35/214.68 (0.16)
92/209.96 (0.44)
42/201.44 (0.21)
35/252.72 (0.14)
1.00 (reference)
2.28 (1.31, 3.97)
1.24 (0.75, 2.03)
0.87 (0.44, 1.72)
p = 0.14
1.00 (reference)
2.43 (1.50, 3.95)
1.31 (0.83, 2.08)
1.26 (0.65, 2.45)
p = 0.77
0–17
>17–27
>27–41
>41–125
Trend:
54/247.55 (0.22)
49/210.32 (0.23)
52/202.49 (0.26)
49/218.43 (0.22)
1.00 (reference)
0.70 (0.40, 1.23)
0.80 (0.36, 1.77)
0.62 (0.25, 1.51)
p = 0.36
1.00 (reference)
0.94 (0.61, 1.45)
1.15 (0.53, 2.46)
1.05 (0.43, 2.58)
p = 0.89
UVR-load in summer in year of FDE (kJ/m2) UVR-load in winter in year of FDE (kJ/m2)
7–28
>28–47
>47–69
>69–96
Trend:
55/198.76 (0.28)
51/214.40 (0.24)
66/249.43 (0.27)
28/189.82 (0.15)
1.00 (reference)
0.89 (0.52, 1.54)
1.08 (0.61, 1.90)
0.60 (0.34, 1.07)
p = 0.23
1.00 (reference)
1.02 (0.68, 1.53)
1.43 (0.86, 2.38)
1.05 (0.58, 1.91)
p = 0.42
1–5
>5–9
>9–14
>14–53
Trend:
72/232.12 (0.31)
32/220.90 (0.15)
39/210.57 (0.19)
57/188.82 (0.30)
1.00 (reference)
0.48 (0.29, 0.81)
0.54 (0.27, 1.09)
0.69 (0.38, 1.25)
p = 0.25
1.00 (reference)
0.65 (0.42, 1.02)
0.83 (0.43, 1.59)
1.17 (0.66, 2.09)
p = 0.62
UVR-load in summer 2 years before FDE (kJ/m2) UVR-load in winter 2 years before FDE (kJ/m2)
7–28
>28–50
>50–69
>69–96
Trend:
55/193.88 (0.28)
64/227.79 (0.28)
52/241.93 (0.22)
33/206.86 (0.16)
1.00 (reference)
1.00 (0.56, 1.77)
0.88 (0.52, 1.49)
0.63 (0.35, 1.15)
p = 0.12
1.00 (reference)
1.10 (0.68, 1.78)
1.14 (0.73, 1.77)
0.95 (0.55, 1.63)
p = 0.96
1–5
>5–9
>9–14
>14–53
Trend:
64/251.92 (0.25)
39/212.00 (0.18)
39/21.68 (0.18)
62/184.86 (0.34)
1.00 (reference)
0.73 (0.41, 1.32)
0.69 (0.35, 1.34)
1.04 (0.58, 1.85)
p = 0.90
1.00 (reference)
0.92 (0.58, 1.45)
0.96 (0.52, 1.77)
1.43 (0.83, 2.46)
p = 0.26
Results in bold denote statistical significance (p < 0.05). Results in italics are for tests of trend.
aAdjusted models for relapse include adjustment for age, sex, and immunomodulatory therapy, and stratified by study site.
bTwo persons did not have data on their summer UVR-load in the 3 years preceding study entry.
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associations with hazard of MS conversion or relapse. For hazard 
of MS conversion (Table 4), whereas there was evidence of an 
inverse association with weekend summer UVR­load, there was 
no association with weekday or holiday summer UVR­load. 
Near­significant trends for winter weekend and holiday time 
in the sun showed no such trends when ambient UVR was 
accounted for in UVR­load parameters. In analyses of relapse 
(Table  5), whereas some summer and winter time in the sun 
variables showed inverse associations with relapse hazard, these 
were largely not robust to adjustment.
association between serum 25(Oh)D  
and conversion to Ms and relapse
As shown in Table 6, neither baseline nor longitudinal serum 
25(OH)D concentration, as­measured or deseasonalized, 
showed a significant association with risk of MS or relapse. For 
the main analysis, serum 25(OH)D level was carried forward as 
a predictor for events occurring within 6 months of the meas­
ure. Expansion forward to include events up to the next serum 
25(OH)D measure did not materially change results (data not 
shown). Adjustment for relevant covariates did not materially 
change the results.
associations between Other Variables  
and conversion to Ms and relapse
As in Table S1 in Supplementary Material, use of any vitamin 
D­containing supplements at baseline (at which point 23.1% 
were using multivitamins containing 200–400 IU vitamin D), 
was not associated with subsequent hazard of MS conversion, 
though an inverse association was evident for subsequent 
relapse hazard. Longitudinal supplement use—by five­year 
review 41.8% were using vitamin D supplements—was not 
associated with either MS or relapse hazard. Restriction to 
supplements with 1,000  IU cholecalciferol or more did not 
materially impact on associations with MS or relapse (data not 
shown).
association between changes  
in sun exposure Behaviors and 
conversion to Ms and relapse
To understand why postonset levels of sun/UVR exposure 
and 25(OH)D levels were not associated with outcomes, we 
examined whether people changed their behavior due to the 
knowledge that UVR exposure and high 25(OH)D levels may 
be beneficial for MS.
We estimated the change in sun/UVR exposure behavior by 
subtracting the baseline data from the 5­year data. On aver­
age, time in the sun was relatively stable over the five years of 
follow­up for most participants, with increases or decreases of 
only 1 category in summer and winter during the week (81.5 
and 86.3%), weekend (75.3 and 88.4%), and holidays (69.2 
and 76.7%). However, a moderate number of participants 
increased or decreased their time in the sun appreciably over 
time, 18–29% increasing or decreasing at least 2 increments 
in summer and 11–23% in winter. Examining spaghetti plots 
(graphical depictions of the change in a parameter over 
TaBle 4 | Postonset longitudinal sun exposure measures and associations with hazard of MS conversion.
summer UVr measures and hazard of Ms conversion Winter UVr measures and hazard of Ms conversion
Failures/person-
years (rate)
hr (95% ci) Failures/person-
years (rate)
hr (95% ci)
Univariable adjusteda Univariable adjusteda
Time in sun during week—summer (h/day) Time in sun during week—winter (h/day)
<1
1 to <2
2 to <3
3 to <4
4+
Trend:
22/115.98 (0.19)
20/114.50 (0.18)
10/51.99 (0.19)
2/22.04 (0.09)
5/68.07 (0.07)
1.00 (reference)
0.96 (0.52, 1.78)
1.02 (0.48, 2.17)
0.48 (0.10, 2.28)
0.41 (0.15, 1.13)
p = 0.064
1.00 (reference)
1.10 (0.56, 2.14)
1.15 (0.49, 2.67)
0.66 (0.13, 3.32)
0.55 (0.18, 1.67)
p = 0.31
<1
1 to < 2
2 to < 3
3 to < 4
4+
Trend:
36/185.55 (0.19)
13/93.23 (0.14)
6/22.40 (0.27)
1/18.22 (0.06)
3/53.18 (0.06)
1.00 (reference)
0.76 (0.40, 1.46)
1.28 (0.53, 3.11)
0.26 (0.03, 1.90)
0.32 (0.09, 1.06)
p = 0.038
1.00 (reference)
0.86 (0.42, 1.73)
1.43 (0.56, 3.62)
0.31 (0.04, 2.48)
0.39 (0.10, 1.51)
p = 0.21
Summer UVR-load during weekdays (kJ/m2) Winter UVR-load during weekdays (kJ/m2)
12–41
>41–62
>62–134
>134–422
Trend:
22/107.06 (0.21)
13/62.76 (0.21)
12/92.97 (0.13)
11/85.57 (0.13)
1.00 (reference)
1.17 (0.60, 2.27)
0.70 (0.35, 1.42)
0.91 (0.36, 2.27)
p = 0.49
1.00 (reference)
1.07 (0.55, 2.09)
0.79 (0.36, 1.72)
0.99 (0.36, 2.74)
p = 0.79
0–7
>7–17
>17–26
>26–198
Trend:
26/132.05 (0.20)
11/59.33 (0.19)
1180.47 (0.14)
10/76.51 (0.13)
1.00 (reference)
1.01 (0.50, 2.05)
0.88 (0.42, 1.85)
0.83 (0.37, 1.86)
p = 0.61
1.00 (reference)
0.98 (0.46, 2.09)
1.09 (0.48, 2.51)
0.93 (0.36, 2.39)
p = 0.93
Time in sun during weekend—summer (h/day) Time in sun during weekend—winter (h/day)
<1
1 to <2
2 to <3
3 to <4
4+
Trend:
6/23.58 (0.25)
18/91.84 (0.20)
15/91.78 (0.16)
12/65.02 (0.19)
8/100.35 (0.08)
1.00 (reference)
0.85 (0.34, 2.10)
0.68 (0.27, 1.71)
0.78 (0.30, 2.06)
0.35 (0.12, 1.02)
p = 0.032
1.00 (reference)
0.95 (0.36, 2.52)
0.75 (0.28, 2.03)
0.87 (0.31, 2.47)
0.49 (0.15, 1.52)
p = 0.18
<1
1 to <2
2 to <3
3 to <4
4+
Trend:
16/61.53 (0.26)
27/145.15 (0.19)
7/65.20 (0.11)
7/41.15 (0.17)
2/59.55 (0.03)
1.00 (reference)
0.73 (0.38, 1.39)
0.43 (0.17, 1.07)
0.65 (0.26, 1.62)
0.15 (0.03, 0.68)
p = 0.006
1.00 (reference)
0.76 (0.39, 1.49)
0.40 (0.16, 1.01)
0.73 (0.28, 1.92)
0.19 (0.03, 1.05)
p = 0.037
Summer UVR-load during weekend (kJ/m2) Winter UVR-load during weekends (kJ/m2)
5–19
>19–50
>50–90
>90–176
Trend:
13/67.09 (0.19)
25/122.38 (0.20)
12/67.58 (0.18)
8/91.31 (0.09)
1.00 (reference)
0.98 (0.49, 1.95)
1.02 (0.43, 2.42)
0.56 (0.18, 1.73)
p = 0.36
1.00 (reference)
1.12 (0.53, 2.35)
0.99 (0.39, 2.51)
0.62 (0.18, 2.16)
p = 0.49
0–4
>4–9
>9–20
>20–121
Trend:
21/83.37 (0.25)
15/119.87 (0.13)
11/66.67 (0.17)
11/78.45 (0.14)
1.00 (reference)
0.54 (0.28, 1.03)
0.77 (0.37, 1.64)
0.83 (0.35, 2.00)
p = 0.66
1.00 (reference)
0.53 (0.26, 1.08)
0.78 (0.33, 1.82)
0.73 (0.24, 2.26)
p = 0.63
Time in sun during holidays—summer (h/day) Time in sun during holidays—winter (h/day)
<1
1 to <2
2 to <3
3 to <4
4+
Trend:
5/18.33 (0.27)
9/66.27 (0.14)
20/86.00 (0.23)
10/55.00 (0.18)
14/143.03 (0.10)
1.00 (reference)
0.57 (0.20, 1.68)
0.99 (0.37, 2.60)
0.72 (0.26, 1.96)
0.42 (0.15, 1.18)
p = 0.083
1.00 (reference)
0.87 (0.24, 3.14)
1.51 (0.49, 4.66)
1.02 (0.36, 2.91)
0.65 (0.22, 1.95)
p = 0.26
<1
1 to <2
2 to <3
3 to <4
4+
Trend:
10/43.49 (0.23)
21/124.83 (0.17)
13/69.93 (0.19)
8/51.36 (0.16)
6/75.74 (0.08)
1.00 (reference)
0.70 (0.34, 1.46)
0.85 (0.38, 1.92)
0.61 (0.24, 1.54)
0.37 (0.13, 1.06)
p = 0.076
1.00 (reference)
0.71 (0.33, 1.52)
0.93 (0.40, 2.16)
0.68 (0.26, 1.76)
0.48 (0.15, 1.54)
p = 0.32
Summer UVR-load during holidays (kJ/m2) Winter UVR-load during holidays (kJ/m2)
3–16
>16–31
>51–64
>64–103
Trend:
14/73.05 (0.19)
20/107.48 (0.19)
15/80.02 (0.19)
8/83.87 (0.10)
1.00 (reference)
0.96 (0.48, 1.92)
1.31 (0.59, 2.94)
0.75 (0.25, 2.21)
 p = 0.76
1.00 (reference)
1.03 (0.51, 2.09)
1.52 (0.68, 3.40)
0.85 (0.27, 2.63)
p = 0.99
0–3
>3–6
>6–14
>14–70
Trend:
16/85.42 (0.19)
16/105.46 (0.15)
12/74.80 (0.16)
13/74.01 (0.18)
1.00 (reference)
0.91 (47, 1.77)
1.09 (0.49, 2.43)
1.61 (0.67, 3.87)
p = 0.34
1.00 (reference)
0.99 (0.51, 1.90)
1.37 (0.59, 3.15)
1.81 (0.68, 4.81)
p = 0.22
Results in bold denote statistical significance (p < 0.05). Results in italics are for tests of trend. Two persons—one each in Queensland and Victoria—did not provide data on sun 
exposure durations. Three persons—one in Victoria and two in Tasmania—did not provide data on sun exposure durations during the week/weekends but did provide this for 
holidays. Eight persons—two in Victoria and six in New South Wales—did not provide data on sun exposures during holidays but did provide this for week/weekends.
aAdjusted models for MS conversion include adjustment for age, sex, and study site.
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multiple time points for each individual within one plot) of 
these changes by study review found them to be consistent in 
direction over the study, only increasing or decreasing, rather 
than more erratic trajectories. It is these persons who greatly 
increased or decreased their sun exposure over the study that 
showed material associations with clinical course. As in Table 7, 
persons who increased their sun exposure between baseline and 
5­year review showed significant reductions in both risk of MS 
and relapse over the preceding interval, whereas those who 
reduced their sun exposure had a greater risk of these outcomes. 
Utilizing UVR­load rather than durations of time in the sun 
produced similar results. Fully expanding the increments of 
change found similar associations to consolidated increments 
(Table S2 in Supplementary Material).
Evaluation of a total­study 25(OH)D trajectory, defined 
whether persons’ 25(OH)D levels stayed low or high from 
TaBle 5 | Postonset longitudinal sun exposure measures and associations with relapse hazard.
summer UVr measures and relapse hazard Winter UVr measures and relapse hazard
Failures/
person-years 
(rate)
hr (95% ci) Failures/person-
years (rate)
hr (95% ci)
Univariable adjusteda Univariable adjusteda
Time in sun during week—summer (h/day) Time in sun during week—winter (h/day)
<1
1 to <2
2 to <3
3 to <4
4+
Trend:
81/306.27 (0.27)
78/259.86 (0.30)
28/117.64 (0.24)
10/43.55 (0.23)
7/85.85 (0.08)
1.00 (reference)
1.37 (0.99, 1.89)
1.11 (0.63, 1.96)
1.17 (0.45, 3.05)
0.45 (0.20, 1.02)
p = 0.23
1.00 (reference)
1.33 (0.96, 1.85)
1.19 (0.70, 2.02)
1.35 (0.49, 3.69)
0.65 (0.28, 1.47)
p = 0.93
<1
1 to <2
2 to <3
3 to <4
4+
Trend:
123/439.51 (0.28)
58/225.86 (0.26)
16/55.34 (0.29)
4/32.60 (0.12)
3/59.87 (0.05)
1.00 (reference)
1.04 (0.75, 1.43)
1.08 (0.60, 1.94)
0.51 (0.22, 1.18)
0.23 (0.08, 0.64)
p = 0.013
1.00 (reference)
1.05 (0.74, 1.48)
1.14 (0.64, 2.01)
0.70 (0.31, 1.58)
0.38 (0.14, 1.02)
p = 0.27
Summer UVR-load during weekdays (kJ/m2) Winter UVR-load during weekdays (kJ/m2)
12–41
>41–62
>62–134
>134–422
Trend:
60/228.55 (0.26)
52/173.53 (0.30)
45/193.22 (0.23)
46/187.89 (0.25)
1.00 (reference)
1.25 (0.83, 1.87)
1.17 (0.76, 1.81)
1.42 (0.89, 2.27)
p = 0.17
1.00 (reference)
1.02 (0.67, 1.55)
1.11 (0.70, 1.74)
1.24 (0.75, 2.06)
p = 0.40
0–7
>7–17
>17–26
>26–198
Trend:
64/250.24 (0.26)
39/175.02 (0.22)
56/185.92 (0.30)
44/172.02 (0.26)
1.00 (reference)
0.92 (0.55, 1.53)
1.56 (0.96, 2.54)
1.16 (0.76, 1.77)
p = 0.18
1.00 (reference)
0.83 (0.49, 1.40)
1.53 (0.92, 2.53)
1.10 (0.70, 1.73)
p = 0.27
Time in sun during weekend–summer (h/day) Time in sun during weekend–winter (h/day)
<1
1 to <2
2 to <3
3 to <4
4+
Trend:
33/125.95 (0.26)
63/222.71 (0.28)
53/180.29 (0.29)
30/127.79 (0.24)
25/156.42 (0.16)
1.00 (reference)
1.13 (0.62, 2.06)
1.23 (0.64, 2.36)
1.08 (0.60, 1.95)
0.83 (0.44, 1.56)
p = 0.55
1.00 (reference)
1.09 (0.63, 1.89)
1.27 (0.71, 2.28)
1.23 (0.69, 2.17)
1.14 (0.62, 2.08)
p = 0.47
<1
1 to <2
2 to <3
3 to <4
4+
Trend:
64/219.50 (0.29)
81/311.06 (0.26)
38/133.56 (0.29)
13/71.12 (0.18)
8/77.92 (0.10)
1.00 (reference)
0.93 (0.62, 1.41)
1.15 (0.75, 1.77)
0.70 (0.37, 1.31)
0.49 (0.21, 1.12)
p = 0.12
1.00 (reference)
0.97 (0.68, 1.39)
1.25 (0.81, 1.94)
0.99 (0.53, 1.84)
0.83 (0.41, 1.65)
p = 0.85
Summer UVR-load during weekend (kJ/m2) Winter UVR-load during weekends (kJ/m2)
5–19
>19–50
>50–90
>90–176
Trend:
51/206.29 (0.25)
62/224.14 (0.28)
51/166.81 (0.31)
39/185.95 (0.21)
1.00 (reference)
1.23 (0.78, 1.93)
1.47 (0.86, 2.53)
1.45 (0.84, 2.50)
p = 0.12
1.00 (reference)
1.35 (0.90, 2.03)
1.31 (0.77, 2.22)
1.36 (0.79, 2.34)
p = 0.28
0–4
>4–9
>9–20
>20–121
Trend:
52/206.15 (0.25)
43/241.98 (0.18)
59/172.99 (0.34)
49/162.08 (0.30)
1.00 (reference)
0.77 (0.49, 1.20)
1.49 (0.87, 2.55)
1.41 (0.89, 2.25)
p = 0.026
1.00 (reference)
0.83 (0.54, 1.26)
1.47 (0.83, 2.60)
1.49 (0.96, 2.33)
p = 0.021
Time in sun during holidays—summer (h/day) Time in sun during holidays—winter (h/day)
<1
1 to <2
2 to <3
3 to <4
4+
Trend:
35/102.50 (0.34)
53/168.81 (0.31)
44/174.09 (0.25)
39/131.26 (0.30)
32/220.96 (0.15)
1.00 (reference)
1.11 (0.61, 1.99)
0.94 (0.52, 1.70)
1.00 (0.60, 1.66)
0.63 (0.35, 1.14)
p = 0.066
1.00 (reference)
1.09 (0.63, 1.87)
1.07 (0.61, 1.85)
1.04 (0.65, 1.66)
0.79 (0.44, 1.41)
p = 0.37
<1
1 to <2
2 to <3
3 to <4
4+
Trend:
42/184.50 (0.23)
80/273.80 (0.29)
43/143.75 (0.30)
18/82.71 (0.22)
20/117.13 (0.17)
1.00 (reference)
1.28 (0.85, 1.93)
1.46 (0.92, 2.30)
0.97 (0.54, 1.73)
0.96 (0.45, 2.02)
p = 0.82
1.00 (reference)
1.18 (0.77, 1.80)
1.55 (0.97, 2.49)
1.23 (0.69, 2.18)
1.32 (0.66, 2.61)
p = 0.21
Summer UVR-load during holidays (kJ/m2) Winter UVR-load during holidays (kJ/m2)
3–16
>16–31
>51–64
>64–103
Trend:
57/201.21 (0.28)
59/206.06 (0.29)
52/183.31 (0.28)
34/177.07 (0.19)
1.00 (reference)
1.05 (0.72, 1.54)
1.35 (0.83, 2.19)
1.05 (0.57, 1.91)
p = 0.56
1.00 (reference)
1.13 (0.79, 1.61)
1.30 (0.82, 2.04)
0.97 (0.54, 1.74)
p = 0.79
0–3
>3–6
>6–14
>14–70
Trend:
49/217.59 (0.23)
50/207.88 (0.24)
43/181.93 (0.24)
60/163.08 (0.37)
1.00 (reference)
1.12 (0.74, 1.69)
1.20 (0.74, 1.95)
1.89 (1.26, 2.84)
p = 0.006
1.00 (reference)
1.14 (0.78, 1.69)
1.22 (0.75, 1.97)
1.89 (1.28, 2.81)
p = 0.006
Results in bold denote statistical significance (p < 0.05). Results in italics are for tests of trend. Two persons—one each in Queensland and Victoria—did not provide data on sun 
exposure durations. Three persons—one in Victoria and two in Tasmania—did not provide data on sun exposure durations during the week/weekends but did provide this for 
holidays. Eight persons—two in Victoria and six in New South Wales—did not provide data on sun exposures during holidays but did provide this for week/weekends.
aAdjusted models for relapse include adjustment for age, sex, and immunomodulatory therapy, and stratified by study site.
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baseline to 5­year review, or whether they changed, utilizing two 
cut­points of 50 and 80 nmol/L, showed no association with MS 
or relapse (Table 7).
Viewing the results of total­study change in sun exposure 
behavior in Kaplan–Meier plot form (Figure 1), these trends are 
more evident. For MS conversion for both summer weekends 
(Figure  1A) and holidays (Figure  1B), whereas those who 
decreased their sun exposure over follow­up had no materially 
different conversion risk compared to those not changing sun 
behavior, participants who increased their sun exposure had sig­
nificantly reduced hazards of MS conversion. For relapse hazard, 
differences were more marked for both weekend (Figure 1C) and 
holiday (Figure 1D), with those who decreased their sun expo­
sure having significantly increased hazard of relapse, whereas 
those who increased sun exposure having significantly reduced 
relapse hazard.
TaBle 6 | As-measured and deseasonalized serum 25(OH)D associations with MS conversion and relapse hazard.
Ms conversion failures/
person-years (rate)
Ms conversion hr (95% ci) relapse failures/ 
person-years (rate)
relapse hr (95% ci)
Univariable adjusteda Univariable adjustedb
Baseline As-measured  
25(OH)D, continuous 10-unit
0.94 (0.86, 1.03)
p = 0.21
0.93 (0.84, 1.03)
p = 0.17
0.98 (0.91, 1.05)
p = 0.56
0.99 (0.93, 1.05)
p = 0.62
Baseline As-measured 25(OH)D
<70
>70–217.6
Trend:
39/259.81 (0.15)
21/168.16 (0.13)
1.00 (reference)
0.84 (0.50, 1.43)
p = 0.52
1.00 (reference)
0.83 (0.47, 1.45)
p = 0.51
128/526.78 (0.25)
68/346.97 (0.20)
1.00 (reference)
0.73 (0.47, 1.15)
p = 0.17
1.00 (reference)
0.75 (0.51, 1.10)
p = 0.14
As-measured 25(OH)D,  
continuous 10-unit
0.98 (0.87, 1.10)
p = 0.74
0.94 (0.83, 1.07)
p = 0.38
1.01 (0.92, 1.11)
p = 0.83
1.00 (0.92, 1.09)
p = 0.97
<70
>70–217.6
Trend:
20/109.93 (0.18)
12/84.97 (0.14)
1.00 (reference)
0.87 (0.44, 1.75)
p = 0.70
1.00 (reference)
0.80 (0.39, 1.65)
p = 0.55
40/199.67 (0.20)
30/153.11 (0.20)
1.00 (reference)
0.89 (0.50, 1.60)
p = 0.70
1.00 (reference)
0.87 (0.50, 1.50)
p = 0.61
As-measured 25(OH)D,  
extrapolated up to 6 months
0.95 (0.86, 1.04)
p = 0.24
0.93 (0.84, 1.03)
p = 0.14
0.98 (0.92, 1.05)
p = 0.56
0.98 (0.93, 1.04)
p = 0.54
<70
>70–217.6
Trend:
34/200.87 (0.17)
21/139.68 (0.15)
1.00 (reference)
0.91 (0.54, 1.51)
p = 0.70
1.00 (reference)
0.86 (0.50, 1.47)
p = 0.58
110/424.36 (0.26)
51/283.63 (0.18)
1.00 (reference)
0.69 (0.46, 1.04)
p = 0.076
1.00 (reference)
0.73 (0.50, 1.05)
p = 0.090
Results in bold denote statistical significance (p < 0.05). Results in italics are for tests of trend.
aAdjusted models for MS include adjustment for age, sex and study site.
bAdjusted models for relapse include adjustment for age, sex, and immunomodulatory medication use, and stratified on study site.
10
Simpson Jr. et al. Sun/Vitamin D and Clinical Course in Early MS
Frontiers in Neurology | www.frontiersin.org February 2018 | Volume 9 | Article 16
changing sun and Vitamin D-related 
Behaviors during Follow-up
Given the impact of changing sun­related behaviors over the 
course of the study on clinical course, we next investigated when 
these changes in sun and related behaviors occurred.
Table 8 shows the changes that occurred over time. On aver­
age, people increased their sun and vitamin D­related behavior 
during follow­up, and most of the change occurred within 
1–2  years after study entry. The uptake of vitamin D supple­
ments occurred somewhat slower, but over the study duration 
the overall use nearly doubled from 24.1 to 40.2%, particularly 
vitamin D­only supplements (rather than multivitamins) where 
use increased 24­fold, from 1.4 to 34.8%. In parallel with this, 
various sun­related attire changed in favor of increased skin 
exposure, including the proportion wearing sunscreen in summer 
all the time (23.5% at 5­year from 18.3% at baseline, p = 0.088) 
or wearing short­sleeved shirts in summer all the time (69.0% at 
5­year from 56.8% at baseline, p = 0.044), whereas the proportion 
reporting never wearing short­sleeved shirts in winter decreased 
from 89.9 to 76.6% (p = 0.004).
We also wanted to know whether people changed their 
behavior more after they converted to MS, as this is a point where 
patients are often being told that they have MS. For each patient, 
we compared the review closest to conversion with the review 
just after conversion of MS (Table 9). There was no consistent 
evidence that conversion to MS was a time point where patients 
changed their behavior to a large extent.
DiscUssiOn
In this prospective cohort study of classic FDE cases followed for 
five years after FDE, we have shown that preonset sun exposure, 
particularly during childhood and adolescence, significantly 
predicts a reduced hazard of subsequent disease activity in 
early MS, including hazards of conversion to MS and of relapse. 
No consistent associations were observed between postonset 
sun exposure or serum 25(OH)D level and clinical outcomes. 
Interestingly, however, we found that those who increased their 
sun exposure during the study had a significantly lower risk of MS 
conversion and relapse than those whose sun exposure decreased 
or remained static.
The finding that preonset sun exposure behavior going back 
to early childhood significantly modulates clinical outcomes 
years later is a novel one. There is strong and consistent evidence 
from case–control studies that low childhood sun exposure 
(2, 5, 50) or vitamin D intake (9) are associated with increased 
risk of later being a MS case. Using the superior longitudinal 
cohort study design, we have likewise found significant protec­
tive associations of childhood and adolescent sun exposure with 
subsequent clinical course. These associations were particularly 
strong for conversion to MS, though there were some weaker 
associations with relapse. In addition, similar associations were 
seen for sun exposure in the period just preceding symptom 
onset, substantiating a role for sun exposure across the pre­FDE 
life course.
Surprisingly, we found no consistent evidence of an associa­
tion between post­FDE sun exposure and either MS conversion 
or relapse hazard, nor between postonset serum 25(OH)D levels 
and clinical course. These null findings were unexpected and 
inconsistent with other observations in support of a role for vita­
min D in MS clinical course (20–24, 26, 27, 51–53). It raises the 
question whether there truly is no association (affirming the null 
hypothesis) or whether the study failed to detect an association (a 
false negative). Despite having the correct temporality in terms of 
assessing sun/vitamin D prior to the outcomes, it is possible that 
there were some unmeasured changes that we did not capture. For 
example, sun exposure and vitamin D supplementation measures 
were carried forward for one year, and unmeasured changes 
in that year could have biased the results toward the null. On 
TaBle 7 | Change in postonset sun exposure measures and 25(OH)D and associations with MS conversion and relapse hazard.
Ms conversion failures/
person-years (rate)
Ms conversion hr (95% ci) relapse failures/
person-years (rate)
relapse hr (95% ci)
Univariable adjusteda Univariable adjustedb
Total study change in time in sun during week—summer (h/day)
−4, −2 h/day
−1, 0, +1 h/day
+2, + 4 h/day
Trend:
7/30.45 (0.23)
49/319.31 (0.15)
1/33.57 (0.03)
1.47 (0.77, 2.82)
1.00 (reference)
0.21 (0.03, 1.31)
p = 0.011
1.62 (0.76, 3.45)
1.00 (reference)
0.24 (0.04, 1.33)
p = 0.020
20/65.96 (0.30)
172/667.91 (0.26)
11/90.01 (0.12)
1.01 (0.66, 1.55)
1.00 (reference)
0.52 (0.24, 1.12)
p = 0.088
1.13 (0.70, 1.83)
1.00 (reference)
0.46 (0.23, 0.92)
p = 0.029
Total study change in summer weekday UVr-load (kJ/m2)
−2 UVR load increments
−1, 0, +1 UVR load increments
+2, +3 UVR load increments
Trend:
2/1.32 (1.51)
36/212.5 (0.17)
17/132.16 (0.13)
7.47 (4.01, 13.89)
1.00 (reference)
0.76 (0.42, 1.37)
p = 0.15
7.24 (2.93, 17.89)
1.00 (reference)
0.63 (0.33, 1.20)
p = 0.054
8/10.30 (0.78)
121/463.36 (0.26)
70/293.40 (0.24)
2.16 (1.11, 4.20)
1.00 (reference)
0.96 (0.64, 1.44)
p = 0.43
1.49 (0.76, 2.90)
1.00 (reference)
0.86 (0.60, 1.24)
p = 0.20
Total study change in time in sun during weekend—summer (h/day)
−4, −2 h/day
−1, 0, +1 h/day
+2, +4 h/day
Trend:
6/25.61 (0.23)
48/285.97 (0.17)
3/71.75 (0.04)
1.40 (0.56, 3.49)
1.00 (reference)
0.25 (0.08, 0.78)
p = 0.008
2.07 (0.78, 5.54)
1.00 (reference)
0.21 (0.06, 0.71)
p = 0.001
39/68.15 (0.57)
145/620.53 (0.23)
19/135.19 (0.14)
2.02 (1.06, 3.84)
1.00 (reference)
0.64 (0.35, 1.18)
p = 0.011
2.23 (1.22, 4.09)
1.00 (reference)
0.59 (0.34, 1.04)
p = 0.002
Total study change in summer weekend UVr-load (kJ/m2)
−2 UVR load increments
−1, 0, +1 UVR load increments
+2, +3 UVR load increments
Trend:
0
31/136.58 (0.23)
24/209.46 (0.12)
–
1.00 (reference)
0.50 (0.29, 0.85)
p = 0.010
–
1.00 (reference)
0.58 (0.33, 1.02)
p = 0.060
2/5.50 (0.36)
113/383.79 (0.29)
84/377.77 (0.22)
0.91 (0.53, 1.56)
1.00 (reference)
0.78 (0.49, 1.23)
p = 0.30
2.71 (1.42, 5.16)
1.00 (reference)
0.92 (0.62, 1.36)
p = 0.55
Total study change in time in sun during holidays—summer (h/day)
−4, −2 h/day
−1, 0, +1 h/day
+2, +4 h/day
Trend:
10/36.72 (0.27)
44/279.28 (0.16)
3/67.33 (0.05)
1.73 (0.91, 3.30)
1.00 (reference)
0.28 (0.08, 0.98)
p = 0.002
2.24 (1.14, 4.41)
1.00 (reference)
0.24 (0.06, 0.92)
p < 0.001
51/110.63 (0.46)
130/564.51 (0.23)
22/148.73 (0.15)
1.71 (1.00, 2.94)
1.00 (reference)
0.70 (0.36, 1.39)
p = 0.020
1.75 (1.07, 2.86)
1.00 (reference)
0.65 (0.36, 1.18)
p = 0.004
Total study change in summer holiday UVr-load (kJ/m2)
−2 UVR load increments
−1, 0, +1 UVR load increments
+2, +3 UVR load increments
Trend:
0
35/136.43 (0.26)
19/197.12 (0.10)
–
1.00 (reference)
0.38 (0.22, 0.66)
p = 0.001
–
1.00 (reference)
0.37 (0.20, 0.67)
p = 0.001
0
129/380.56 (0.34)
67/345.64 (0.19)
–
1.00 (reference)
0.62 (0.41, 0.96)
p = 0.033
–
1.00 (reference)
0.65 (0.45, 0.94)
p = 0.021
Total study change in time in sun during week—winter (h/day)
−4, −2 h/day
−1, 0, +1 h/day
+2, +4 h/day
Trend:
6/41.44 (0.15)
47/317.56 (0.15)
4/24.33 (0.16)
0.97 (0.44, 2.13)
1.00 (reference)
1.14 (0.43, 3.03)
p = 0.81
1.38 (0.60, 3.18)
1.00 (reference)
0.90 (0.31, 2.65)
p = 0.51
15/72.70 (0.21)
176/705.91 (0.25)
12/45.25 (0.27)
0.81 (0.49, 1.36)
1.00 (reference)
1.13 (0.45, 2.81)
p = 0.48
1.11 (0.70, 1.77)
1.00 (reference)
1.07 (0.42, 2.69)
p = 0.93
Total study change in winter weekday UVr-load (kJ/m2)
−2 UVR load increments
−1, 0, +1 UVR load increments
+2, +3 UVR load increments
Trend:
0
36/215.45 (0.17)
19/130.58 (0.15)
–
1.00 (reference)
0.88 (0.51, 1.52)
p = 0.66
–
1.00 (reference)
0.62 (0.32, 1.17)
p = 0.14
2/5.50 (0.36)
119/493.59 (0.24)
78/267.97 (0.29)
1.05 (0.56, 1.97)
1.00 (reference)
1.11 (0.65, 1.89)
p = 0.71
2.82 (1.49, 5.36)
1.00 (reference)
0.95 (0.57, 1.57)
p = 0.76
Total study change in time in sun during weekend—winter (h/day)
−4, −2 h/day
−1, 0, +1 h/day
+2, +4 h/day
Trend:
3/17.99 (0.17)
52/337.52 (0.15)
2/27.81 (0.07)
1.11 (0.32, 3.80)
1.00 (reference)
0.48 (0.11, 2.09)
p = 0.36
1.39 (0.41, 4.70)
1.00 (reference)
0.32 (0.06, 1.62)
p = 0.099
11/49.77 (0.22)
187/724.03 (0.26)
5/50.08 (0.10)
0.82 (0.46, 1.48)
1.00 (reference)
0.44 (0.15, 1.24)
p = 0.33
1.00 (0.59, 1.71)
1.00 (reference)
0.46 (0.18, 1.22)
p = 0.16
Total study change in winter weekend UVr-load (kJ/m2)
−2 UVR load increments
−1, 0, +1 UVR load increments
+2, +3 UVR load increments
Trend:
0
34/209.04 (0.16)
21/136.99 (0.15)
–
1.00 (reference)
0.93 (0.55, 1.56)
p = 0.78
–
1.00 (reference)
0.96 (0.54, 1.72)
p = 0.90
0
122/484.95 (0.25)
77/282.11 (0.27)
–
1.00 (reference)
0.99 (0.52, 1.86)
p = 0.96
–
1.00 (reference)
1.04 (0.60, 1.79)
p = 0.90
(Continued )
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Ms conversion failures/
person-years (rate)
Ms conversion hr (95% ci) relapse failures/
person-years (rate)
relapse hr (95% ci)
Univariable adjusteda Univariable adjustedb
Total study change in time in sun during holidays—winter (h/day)
−4, −2 h/day
−1, 0, +1 h/day
+2, +4 h/day
Trend:
6/35.05 (0.17)
46/304.72 (0.15)
5/43.57 (0.12)
1.13 (0.49, 2.60)
1.00 (reference)
0.76 (0.28, 2.10)
p = 0.53
1.14 (0.47, 2.75)
1.00 (reference)
0.56 (0.17, 1.80)
p = 0.29
15/77.18 (0.19)
176/743.91 (0.27)
12/102.78 (0.12)
0.70 (0.42, 1.17)
1.00 (reference)
0.45 (0.23, 0.89)
p = 0.19
0.87 (0.56, 1.35)
1.00 (reference)
0.50 (0.27, 0.95)
p = 0.087
Total study change in winter holiday UVr-load (kJ/m2)
−2 UVR load increments
−1, 0, +1 UVR load increments
+2, +3 UVR load increments
Trend:
1/1.04 (0.96)
34/197.39 (0.17)
17/122.65 (0.14)
4.31 (2.54, 7.32)
1.00 (reference)
0.80 (0.45, 1.41)
p = 0.29
2.18 (1.03, 4.59)
1.00 (reference)
0.60 (0.28, 1.27)
p = 0.10
4/16.63 (0.24)
125/443.37 (0.28)
66/260.25 (0.25)
0.69 (0.34, 1.41)
1.00 (reference)
0.87 (0.55, 1.38)
p = 0.68
0.90 (0.42, 1.94)
1.00 (reference)
0.84 (0.55, 1.28)
p = 0.43
change in as-measured 25(Oh)D during study—50 nmol/l cutoff
Low all
High, then low
High all
Low, then high
Trend:
7/35.37 (0.20)
7/46.92 (0.15)
32/255.83 (0.13)
14/89.85 (0.16)
1.00 (reference)
0.79 (0.31, 2.02)
0.67 (0.30, 1.49)
0.83 (0.36, 1.96)
p = 0.68
1.00 (reference)
0.44 (0.15, 1.26)
0.52 (0.25, 1.12)
0.59 (0.24, 1.45)
p = 0.57
13/84.71 (0.15)
9/71.70 (0.13)
131/511.92 (0.26)
43/205.43 (0.21)
1.00 (reference)
0.71 (0.30, 1.69)
1.43 (0.75, 2.75)
1.31 (0.64, 2.65)
p = 0.23
1.00 (reference)
0.76 (0.34, 1.70)
1.36 (0.76, 2.42)
1.14 (0.61, 2.13)
p = 0.48
change in as-measured 25(Oh)D during study—80 nmol/l cutoff
Low all
High, then low
High all
Low, then high
Trend:
32/249.89 (0.13)
4/35.02 (0.11)
7/59.80 (0.12)
17/83.26 (0.20)
1.00 (reference)
0.93 (0.29, 2.96)
0.94 (0.45, 1.94)
1.61 (0.88, 2.95)
p = 0.19
1.00 (reference)
0.80 (0.23, 2.77)
0.95 (0.45, 1.98)
1.52 (0.79, 2.90)
p = 0.30
93/446.95 (0.21)
233/81.08 (0.28)
21/116.29 (0.18)
59/229.44 (0.26)
1.00 (reference)
1.08 (0.52, 2.26)
0.80 (0.44, 1.47)
1.28 (0.77, 2.14)
p = 0.51
1.00 (reference)
1.07 (0.57, 2.01)
0.74 (0.42, 1.29)
1.08 (0.70, 1.65)
p = 0.99
change in deseasonalized 25(Oh)D during study—50 nmol/l cutoff
Low all
High, then low
High all
Low, then high
Trend:
6/32.84 (0.18)
7/47.73 (0.15)
32/246.29 (0.13)
15/101.11 (0.15)
1.00 (reference)
0.84 (0.31, 2.29)
0.75 (0.32, 1.78)
0.86 (0.34, 2.13)
p = 0.77
1.00 (reference)
0.52 (0.19, 1.47)
0.58 (0.25, 1.35)
0.52 (0.19, 1.41)
p = 0.35
12/73.56 (0.16)
9/72.50 (0.12)
130/505.75 (0.25)
45/221.95 (0.20)
1.00 (reference)
0.68 (0.28, 1.65)
1.38 (0.69, 2.75)
1.24 (0.60, 2.55)
p = 0.30
1.00 (reference)
0.78 (0.35, 1.72)
1.26 (0.69, 2.33)
1.09 (0.58, 2.05)
p = 0.63
change in deseasonalized 25(Oh)D during study—80 nmol/l cut-off
Low all
High, then low
High all
Low, then high
Trend:
30/225.35 (0.13)
6/34.37 (0.18)
8/66.84 (0.12)
16/101.41 (0.16)
1.00 (reference)
1.34 (0.53, 3.37)
0.92 (0.45, 1.89)
1.21 (0.66, 2.22)
p = 0.65
1.00 (reference)
1.36 (0.60, 3.07)
0.83 (0.38, 1.78)
1.03 (0.52, 2.05)
p = 0.94
100/419.35 (0.24)
25/82.70 (0.30)
23/122.35 (0.19)
48/249.36 (0.19)
1.00 (reference)
1.04 (0.51, 2.10)
0.73 (0.41, 1.31)
0.84 (0.49, 1.45)
p = 0.42
1.00 (reference)
0.98 (0.55, 1.75)
0.67 (0.40, 1.11)
0.73 (0.46, 1.15)
p = 0.11
Results in bold denote statistical significance (p < 0.05). Results in italics are for tests of trend.
aAdjusted models for MS include adjustment for age, sex, and study site.
bAdjusted models for relapse include adjustment for age, sex, and immunomodulatory medication use, and stratified on study site.
UVR, ultraviolet radiation; 25(OH)D, 25-hydroxyvitamin D.
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average, people increased their sun and vitamin D­related behav­
ior during the study and we found that most of the sun­related 
changes occurred within 1–2  years after study entry, whereas 
vitamin D supplementation uptake occurred somewhat slower. 
This may suggest a Hawthorne effect, where people enrolled in 
a study are inclined to change the behavior being evaluated only 
because it is being studied. It is possible that this limited our abil­
ity to detect an association. We examined whether conversion 
to MS was a timepoint where patients changed their behavior, 
as they were told that they have MS and may have searched for 
potentially beneficial lifestyle behaviors, but there was no strong 
evidence for this. Certainly, however, the marked increases in sun 
exposure and vitamin D supplementation during follow­up may 
have impacted on our ability to assess these parameters’ associa­
tions with clinical outcomes, since they would no longer be solely 
distributed by clinical phenotype.
We were unable to fully evaluate whether these findings 
partly reflected disease or medical­initiated alterations to these 
exposures over time due to the non­randomized design. Our 
favored interpretation is that these results indicate behavior 
change by participants in sun exposure/vitamin D­related 
parameters did occur after disease onset; this in keeping with 
results in this cohort seen for diet and supplementation behavior 
(54, 55). This interpretation is guided partly by our finding of 
significant behavior change in this cohort, but also by the 
results from our analyses of total­study change in sun behavior 
00.0
52.0
05.0
57.0
00.1
0 1000 2000 3000
Analysis time from symptom onset (days)
Decrease 1-4hr/d No change Increase 1-4hr/d
Total-study change in summertime in sun on holidays
MS conversion risk
ptrend=0.002
00.0
52.0
05.0
57.0
00.1
0 1000 2000 3000
Analysis time from symptom onset (days)
Decrease 1-4hr/d No change Increase 1-4hr/d
Total-study change in summertime in sun on weekends
MS conversion risk
ptrend=0.008
00.0
52.0
05.0
57.0
00.1
0 1000 2000 3000
Analysis time from symptom onset (days)
Decrease 1-4hr/d No change Increase 1-4hr/d
Total-study change in summertime in sun on holidays
Relapse risk
ptrend=0.020
00.0
52.0
05.0
57.0
00.1
0 1000 2000 3000
Analysis time from symptom onset (days)
Decrease 1-4hr/d No change Increase 1-4hr/d
Total-study change in summertime in sun on weekends
Relapse risk
ptrend=0.011
FigUre 1 | Kaplan–Meier plots of recreational summer sun exposure durations and risk of conversion to multiple sclerosis (MS) and of relapse. (a) summer 
weekend and MS; (B) summer weekend and relapse; (c) summer holidays and MS; and (D) summer holidays and relapse.
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and its association with MS conversion and relapse hazard. In 
those change analyses, we found three trajectories divided by 
participants’ change in sun behavior. In one group, there was 
little or no change in UVR, of whom roughly 75% converted to 
MS and 60% failed by relapse. Among the subset that decreased 
their UVR by two or more levels, whereas their risk of MS was 
no different to the reference level, the proportion that failed 
by relapse was 80–90%, significantly greater than those whose 
UVR was unchanged. This result may be reflective of reverse 
causality – those who had greater clinical activity could realize 
decreased sun exposure. The other group, those who increased 
UVR during the study, is of interest – this group realized sig­
nificantly lower proportions converting to MS (<25%) and also 
lower proportions failing by relapse (<50%). This is not what 
one would expect by reverse causality and may allude to some 
beneficial effect of increasing sun exposure levels on the clinical 
course of MS. No associations were seen for levels of 25(OH)D, 
changes in 25(OH)D, vitamin D supplementation nor changes 
in vitamin D supplementation, which could suggest that UVR 
interventions, such as narrow­band UVR (39), could be more 
promising in producing beneficial outcomes for people with MS 
than vitamin D supplementation alone.
Our study is unique in that it collected detailed prospective 
data on sun exposure, 25(OH)D levels and a large range of poten­
tial confounding variables. Though some measurement error of 
past sun exposure cannot be excluded, we used questions with 
demonstrated validity and reliability (7). The multicentre nature 
of the cohort across the east coast of Australia allows it to be 
nationally representative, and Australia is demographically and 
culturally similar to other European­descent populations where 
MS is prevalent. The prospective nature of the follow­up post­
FDE with multiple time points of assessment would moderate the 
impact of reverse causality. The restriction to those with a classic 
FDE reduces the power of the study but increases the specificity 
of the findings. We do not have data on MRI metrics of disease 
activity largely due to the heterogeneous nature of the baseline 
scans collected (56).
In conclusion, we found that preonset sun exposure was pro­
tective against subsequent conversion to MS and relapse. While 
we did not find an association between postonset sun exposure or 
TaBle 8 | Distribution of sun/vitamin D behavioral variables during study, by years poststudy entry.
Baseline 1–1.99 years 
postentry
2–2.99 years 
postentry
3–3.99 years 
postentry
4–4.99 years 
postentry
5+ years 
postentry
Test for difference  
by chi-square test
summer weekday UVr-load (kJ/m2)
12–41
>41–62
>62–134
>134–422
76 (55.9%)
24 (17.7%)
29 (21.3%)
7 (5.2%)
43 (32.6%)
23 (17.4%)
34 (25.8%)*
32 (24.2%)**
16 (12.8%)
40 (32.0%)**
30 (24.0%)**
39 (31.2%)**
15 (17.8%)
24 (22.0%)**
28 (25.7%)**
42 (38.5%)**
10 (7.8%)
28 (21.7%)**
41 (31.8%)**
50 (38.8%)**
7 (7.9%)
24 (27.0%)**
28 (31.5%)**
30 (33.7%)**
p < 0.001
summer weekend UVr-load (kJ/m2)
5–19
>19–50
>50–90
>90–176
59 (43.4%)
63 (46.3%)
9 (6.6%)
5 (3.7%)
341 (23.5%)
47 (35.7%)
28 (21.2%)**
26 (19.7%)**
21 (16.8%)
15 (12.0%)
47 (37.6%)**
42 (33.6%)**
12 (11.0%)
21 (19.3%)
31 (28.4%)**
45 (41.3%)**
18 (14.0%)
17 (13.2%)
49 (38.0%)**
45 (34.9%)**
15 (16.9%)
8 (9.0%)
32 (36.0%)**
34 (38.2%)**
p < 0.001
summer holiday UVr-load (kJ/m2)
3–16
>16–31
>31–64
>64–103
58 (45.0%)
56 (43.4%)
12 (9.3%)
3 (2.3%)
37 (28.5%)
41 (31.5%)
25 (19.2%)*
27 (20.8%)**
20 (16.0%)
15 (12.0%)
45 (36.0%)**
45 (36.0%)**
11 (10.2%)
19 (17.6%)
34 (31.5%)**
44 (40.7%)**
21 (16.2%)
21 (16.2%)
49 (37.7%)**
39 (30.0%)**
11 (12.2%)
16 (17.8%)
25 (27.8%)**
38 (42.2%)**
p < 0.001
Winter weekday UVr-load (kJ/m2)
0–7
>7–17
>17–26
>26–198
81 (59.6%)
26 (19.1%)
12 (8.8%)
17 (12.5%)
52 (39.4%)
20 (15.2%)
28 (21.2%)*
32 (24.2%)*
12 (9.6%)
36 (28.8%)**
41 (32.8%)**
36 (28.8%)**
14 (12.8%)
29 (26.6%)**
38 (34.9%)**
28 (25.7%)**
21 (16.3%)
31 (24.0%)**
34 (26.4%)**
43 (33.3%)**
17 (19.1%)
25 (28.1%)**
23 (25.8%)**
24 (27.0%)**
p < 0.001
Winter weekend UVr-load (kJ/m2)
0–4
>4–9
>9–20
>20–121
58 (42.7%)
55 (40.4%)
19 (14.0%)
4 (2.9%)
42 (31.8%)
41 (31.1%)
26 (19.7%)
23 (17.4%)**
21 (16.8%)
25 (20.0%)
29 (23.2%)**
50 (40.0%)**
12 (11.0%)
29 (26.6%)*
37 (33.9%)**
31 (28.4%)**
23 (17.8%)
32 (24.8%)
37 (28.7%)**
37 (28.7%)**
10 (11.2%)
20 (22.5%)
26 (29.2%)**
33 (37.1%)**
p < 0.001
Winter holiday UVr-load (kJ/m2)
0–3
>3–6
>6–14
>14–70
57 (44.5%)
44 (34.4%)
22 (17.2%)
5 (3.9%)
40 (33.1%)
35 (28.9%)
23 (19.0%)*
23 (19.0%)**
20 (17.5%)
22 (19.3%)
24 (21.1%)**
48 (42.1%)**
8 (7.9%)
30 (29.7%)**
34 (33.7%)*
29 (28.7%)**
31 (24.4%)
22 (17.3%)
39 (30.7%)**
35 (27.6%)**
12 (13.6%)
17 (19.3%)
26 (29.6%)**
33 (37.5%)**
p < 0.001
Taking vitamin D-containing supplement at review?
No
Yes
110 (75.9%)
35 (24.1%)
115 (81.6%)
26 (18.4%)
99 (75.6%)
32 (24.4%)
73 (67.0%)
36 (33.0%)
77 (58.8%)
54 (41.2%)*
55 (59.8%)
37 (40.2%)*
p < 0.001
Taking high-dose (1,000 iU+) vitamin D-containing supplement at review?
No
Yes
143 (98.6%)
2 (1.4%)
139 (98.6%)
2 (1.4%)
123 (93.9%)
8 (6.1%)
95 (87.2%)
14 (12.8%)*
98 (74.8%)
33 (25.2%)**
60 (65.2%)
32 (34.8%)**
p < 0.001
Restricted to persons followed up to 5-year review. Test for difference of strata by review assessed by multinomial logistic regression.
Results in bold denote statistical significance (p < 0.05). Results in italics are for tests of trend.
*p < 0.05.
**p < 0.001.
UVR, ultraviolet radiation.
14
Simpson Jr. et al. Sun/Vitamin D and Clinical Course in Early MS
Frontiers in Neurology | www.frontiersin.org February 2018 | Volume 9 | Article 16
serum 25(OH)D level and clinical course, possibly due to disease 
or medically induced behavior change, those participants who 
markedly increased their sun exposure demonstrated a reduced 
MS conversion and relapse hazard compared to those who did 
not. Clinical trials investigating the effects of vitamin D supple­
mentation and narrow­band UVR exposure will be beneficial to 
further substantiate the role of UVR and vitamin D in MS clinical 
course.
aUsiMMUne/aUslOng inVesTigaTOrs 
grOUP lisT
The members of the Ausimmune/AusLong Investigators Group 
are as follows: Robyn M. Lucas (National Centre for Epidemiology 
and Population Health, Canberra), Keith Dear (Duke Kunshan 
University, Kunshan, China), Anne­Louise Ponsonby and Terry 
Dwyer (Murdoch Childrens Research Institute, Melbourne, 
TaBle 9 | Distribution of sun/vitamin D behavioral variables during study relative to MS conversion. Table restricted to those who converted to MS and who were 
followed up to 5-year review.
Baseline Postentry, prior to Ms conversion Post-Ms conversion 5-Year review Test for difference by chi-square test
summer weekday UVr-load (kJ/m2)
12–41
>41–62
>62–134
>134–422
57 (59.4%)
17 (17.7%)
16 (16.7%)
6 (6.3%)
11 (18.6%)
14 (23.7%)*
20 (33.9%)**
14 (23.7%)**
50 (18.5%)
73 (26.9%)**
69 (25.5%)**
79 (29.2%)**
10 (10.0%)
31 (31.0%)**
33 (33.0%)**
26 (26.0%)**
p < 0.001
summer weekend UVr-load (kJ/m2)
5–19
>19–50
>50–90
>90–176
46 (47.9%)
41 (42.7%)
5 (5.2%)
4 (4.2%)
7 (11.9%)
19 (32.2%)*
22 (37.3%)
11 (18.6%)
62 (22.9%)
53 (19.6%)**
85 (31.4%)**
71 (26.2%)**
20 (20.0%)
12 (12.0%)**
39 (39.0%)**
29 (29.0%)**
p < 0.001
summer holiday UVr-load (kJ/m2)
3–16
>16–31
>31–64
>64–103
43 (47.3%)
36 (39.6%)
9 (9.9%)
3 (3.3%)
7 (11.9%)
16 (27.1%)*
26 (44.1%)
10 (17.0%)
63 (23.5%)
56 (20.9%)**
72 (26.9%)**
77 (28.7%)**
18 (18.0%)
21 (21.0%)**
33 (33.0%)**
28 (28.0%)**
p < 0.001
Winter weekday UVr-load (kJ/m2)
0–7
>7–17
>17–26
>26–198
59 (61.5%)
18 (18.8%)
7 (7.3%)
12 (12.5%)
16 (27.1%)
8 (13.6%)
22 (37.3%)**
13 (22.0%)**
53 (19.6%)
79 (29.2%)**
68 (25.1%)**
71 (26.2%)**
16 (16.0%)
27 (27.0%)**
28 (28.0%)**
29 (29.0%)**
p < 0.001
Winter weekend UVr-load (kJ/m2)
0–4
>4–9
>9–20
>20–121
46 (47.9%)
36 (37.5%)
11 (11.5%)
3 (3.1%)
11 (18.6%)
15 (25.4%)
15 (25.4%)
18 (30.5%)*
61 (22.5%)
76 (28.0%)*
73 (26.9%)**
61 (22.5%)**
12 (12.0%)
25 (25.0%)**
29 (29.0%)**
34 (34.0%)**
p < 0.001
Winter holiday UVr-load (kJ/m2)
0–3
>3–6
>6–14
>14–70
44 (48.4%)
26 (28.6%)
17 (18.7%)
4 (4.4%)
8 (15.1%)
18 (34.0%)*
9 (17.0%)
18 (34.0%)
66 (26.3%)
60 (23.9%)
64 (25.5%)*
61 (24.3%)**
16 (16.2%)
19 (19.2%)**
32 (32.3%)**
32 (32.3%)**
p < 0.001
Taking vitamin D-containing supplement at review?
No
Yes
75 (75.0%)
25 (25.0%)
46 (74.2%)
16 (25.8%)
201 (73.1%)
74 (26.9%)
56 (56.0%)
44 (44.0%)*
p = 0.006
Taking high-dose (1,000 iU +) vitamin D-containing supplement at review?
No
Yes
98 (98.0%)
2 (2.0%)
60 (96.8%)
2 (3.2%)
243 (88.4%)
32 (11.6%)*
61 (61.0%)
39 (39.0%)**
p < 0.001
Test for difference of strata by review assessed by multinomial logistic regression.
Results in bold denote statistical significance (p < 0.05). Results in italics are for tests of trend.
*p < 0.05.
**p < 0.001.
UVR, ultraviolet radiation.
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Australia), Ingrid van der Mei, Leigh Blizzard, Steve Simpson, 
Jr., and Bruce V. Taylor (Menzies Institute for Medical Research, 
University of Tasmania, Hobart, Australia), Simon Broadley 
(School of Medicine, Griffith University, Gold Coast Campus, 
Australia), Trevor Kilpatrick (Centre for Neurosciences, 
Department of Anatomy and Neuroscience, University of 
Melbourne, Melbourne, Australia), David Williams and Jeanette 
Lechner­Scott (University of Newcastle, Newcastle, Australia), 
Cameron Shaw and Caron Chapman (Barwon Health, Geelong, 
Australia), Alan Coulthard (University of Queensland, Brisbane, 
Australia), Michael P. Pender (The University of Queensland, 
Brisbane, Australia), and Patricia Valery (QIMR Berghofer 
Medical Research Institute, Brisbane, Australia).
eThics sTaTeMenT
The ethics committee of all participating centers approved the 
study; all participants signed written informed consent.
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